Affiliation:
1. Pediatric Pulmonary Institute and CF Center, Rappaport Children’s Hospital, Rambam Health Care Campus, Haifa 3109601, Israel
2. Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa 3525422, Israel
Abstract
The introduction of mutation-specific therapy led to a revolution in cystic fibrosis (CF) care. These advances in CF therapies have changed the disease profile from a severe incurable disease with limited survival to a treatable disease with improved quality of life and survival into adulthood. CF patients are now able to plan their future, including marriage and parenthood. Side by side with the optimism, new issues and concerns are arising, including fertility and preparation for pregnancy, maternal and fetal care during pregnancy, and post-partum care. While cystic fibrosis transmembrane regulator (CFTR) modulators show promising results for improving CF lung disease, data on their safety in pregnancy are still limited. We performed a literature review on pregnancy in CF from the past, with the first described pregnancy in 1960, through the current fascinating changes in the era of CFTR modulators, to ongoing studies and future directions. Current advances in knowledge give hope for improved outcomes of pregnancy, towards the best possible prognosis for the mother and for the baby.
Reference62 articles.
1. Impact of pregnancy on women with cystic fibrosis;McMullen;Chest,2006
2. Pregnancy and Delivery in a Patient with Cystic Fibrosis of the Pancreas: Report of a case;Siegel;Obstet. Gynecol.,1960
3. Fertility and Pregnancy in Cystic Fibrosis;Shteinberg;Chest,2021
4. Cystic Fibrosis Foundation (2021). Patient Registry 2020 Annual Data Report, Cystic Fibrosis Foundation.
5. Pregnancy outcome in women with cystic fibrosis and poor pulmonary function;Reynaud;J. Cyst. Fibros.,2020
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献